Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0007 | 0.0542 | 1 |
Echinococcus granulosus | histone lysine N methyltransferase MLL3 | 0.0009 | 0.0956 | 0.0482 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0004 | 0.0127 | 0.0127 |
Schistosoma mansoni | cpg binding protein | 0.0029 | 0.4403 | 0.4403 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0007 | 0.0542 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0044 | 0.697 | 0.697 |
Echinococcus granulosus | cpg binding protein | 0.0031 | 0.4688 | 0.6388 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0007 | 0.0542 | 1 |
Trichomonas vaginalis | helicase, putative | 0.0007 | 0.0542 | 1 |
Loa Loa (eye worm) | CXXC zinc finger family protein | 0.0029 | 0.4403 | 0.5732 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0007 | 0.0542 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0044 | 0.697 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0007 | 0.0542 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0007 | 0.0542 | 1 |
Echinococcus multilocularis | cpg binding protein | 0.0031 | 0.4688 | 0.6388 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0044 | 0.697 | 0.697 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0044 | 0.697 | 0.697 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0044 | 0.697 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0044 | 0.697 | 1 |
Onchocerca volvulus | 0.0029 | 0.4403 | 0.5 | |
Plasmodium falciparum | zinc finger protein, putative | 0.0003 | 0 | 0.5 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0007 | 0.0651 | 0.0651 |
Schistosoma mansoni | cpg binding protein | 0.0031 | 0.4688 | 0.4688 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0044 | 0.697 | 1 |
Brugia malayi | CXXC zinc finger family protein | 0.0029 | 0.4403 | 0.5746 |
Schistosoma mansoni | cpg binding protein | 0.0031 | 0.4688 | 0.4688 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0007 | 0.0542 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0007 | 0.0542 | 1 |
Echinococcus multilocularis | histone lysine N methyltransferase MLL3 | 0.0009 | 0.0956 | 0.0482 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0044 | 0.697 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0007 | 0.0542 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0044 | 0.697 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0007 | 0.0542 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0007 | 0.0542 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0007 | 0.0542 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0007 | 0.0542 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0003 | 0 | 0.5 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0007 | 0.0542 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0007 | 0.0542 | 1 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0007 | 0.0542 | 1 |
Toxoplasma gondii | histone lysine methyltransferase SET1 | 0.0056 | 0.8869 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0007 | 0.0542 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.